$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
乐伐替尼治疗甲状腺癌的推荐剂量及不良反应
2025-10-19 11:44:20
Check Details
卡博替尼不良反应以及适应症总结
2025-10-19 11:44:20
Check Details
多吉美抗肿瘤治疗之甲状腺癌
2025-10-19 11:44:20
Check Details
多吉美使分化型甲状腺癌死亡的风险41%
2025-10-19 11:44:20
Check Details
乐伐替尼和索拉非尼治疗难治性甲状腺癌的新方法
2025-10-19 11:44:20
Check Details
乐伐替尼等酪氨酸激酶抑制剂治疗碘难治性晚期甲状腺癌
2025-10-19 11:44:20
Check Details
乐伐替尼等酪氨酸激酶抑制剂治疗碘难治性晚期甲状腺癌(二)
2025-10-19 11:44:20
Check Details
乐伐替尼等酪氨酸激酶抑制剂治疗碘难治性晚期甲状腺癌(三)
2025-10-19 11:44:20
Check Details
乐伐替尼在碘难治性甲状腺癌中的应用——瑞士回顾性分析
2025-10-19 11:44:20
Check Details
乐伐替尼治疗碘难治性甲状腺癌:SELECT研究数据更新
2025-10-19 11:44:20
Check Details
索拉非尼治疗碘难治性分化型甲状腺癌:3期试验
2025-10-19 11:44:20
Check Details
乐伐替尼等酪氨酸激酶抑制剂治疗碘难治性晚期甲状腺癌(四)
2025-10-19 11:44:20
Check Details
1
2
...
8490
8491
8492
8493
8494
8495
8496
...
10209
10210
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Odevixibat: Targeting IBAT to Transform Cholestatic Liver Disease Treatment
2
A Precision FGFR Inhibitor for Cholangiocarcinoma
3
A Revolutionary Targeted Therapy for Hematological Malignancies
4
A New Option for Advanced Renal Cell Carcinoma Treatment
5
Trametinib (Mekinist): Precision MEK1/2 Inhibition Transforming Cancer Care Short Description:
6
Pirtobrutinib: A Novel BTK Inhibitor Offering Hope for Hematologic Cancer Patients Short Description:
7
Olaparib Plus Pembrolizumab Maintenance Therapy for Metastatic Pancreatic Cancer: Findings from the POLAR Phase II Basket Trial
8
Sacituzumab Govitecan: Trop-2 Targeted ADC Clinical Medication Guide
9
Fulvestrant (Faslodex) Breast Cancer Guide: Indications, Dosage and Safety Specifications
10
Avatrombopag (Doptelet) Dosage: Dose Adjustment and Medication Guidelines for Different Indications
11
Effects of Gilteritinib (Xospata) Discontinuation in Acute Myeloid Leukemia Treatment
12
Avatrombopag vs Hetrombopag: Full Comparison of TPO Receptor Agonists for Thrombocytopenia